FTSE 100 news / Companies and sectors / AstraZeneca / AstraZeneca to present four Phase III trials at ESMO 2026
AstraZeneca to present four Phase III trials at ESMO 2026
+6.3 strongly positive
AstraZeneca will present overall survival data from four Phase III trials at ESMO.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| Business Wire | 1 | +9.2 |
| StreetInsider | 1 | +7.5 |
| Mirage News | 1 | +7.0 |
| MarketScreener | 1 | +6.7 |
| TipRanks | 1 | +5.8 |
| AD HOC NEWS | 1 | +1.7 |
Day by day
Tuesday 20 October 2026
AstraZeneca will present overall survival data from four Phase III trials at ESMO.
- +9.2 AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
Overall survival data in Presidential Symposia, a prestigious slot. - +7.5 AstraZeneca to present data from four Phase III trials at ESMO 2026
Four Phase III trials to be presented at ESMO. - +7.0 AstraZeneca to Present Survival Data From Four Trials at ESMO 2026
Survival data from four trials at ESMO. - +6.7 AstraZeneca to unveil major oncology advances at the 2026 ESMO Congress
Major oncology advances to be unveiled. - +5.8 AstraZeneca announces new data across portfolio at ESMO 2026
New data across portfolio at ESMO. - +1.7 AstraZeneca stock: ESMO event on October 26 ahead of Xetra open - ad-hoc-news.de
Upcoming ESMO event preview, mildly positive.